On the one hand, this result is consistent with previous real-world study data showing that ICI efficacies against BRAF-, HER2-, MET-, or RET-NSCLC patients were close to the efficacy observed in unselected NSCLC patients (29). Here, ERBB2 is linked to non-small cell lung carcinoma.